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ABSTRACT
The diagnosis of bone metastases is an event with cer-
tain consequences for the patient. They often mean pain
and can also mean pathological fractures, hypercalce-
mia, and spinal cord compression, all synonymous with
a diminished quality of life and often also hospitaliza-
tion. Since the advent of the intravenous bisphospho-
nates, things began to look a bit brighter for patients
with bone metastases—bone destruction was kept at
bay a little longer. The next generation of bone metas-
tasis treatments is well on its way in clinical develop-
ment, and among them, the most advanced drug is
denosumab. Denosumab is a fully human monoclonal
antibody that inhibits osteoclast maturation, activation,
andfunctionbybindingtoreceptoractivatorofnuclear
factor kappa B ligand, with the final result being a re-
duced rate of bone resorption. In this review, we give an
overview of relevant preclinical and clinical data re-
garding the use of denosumab in patients with solid tu-
mors in general and prostate cancer in particular. The
Oncologist 2011;16:136–145
INTRODUCTION
The bone is a very common site of metastasis in patients
with advanced cancer. Skeletal metastases are most com-
mon in breast and prostate cancer, but virtually any ad-
vanced cancer may disseminate to the bone. Multiple
myeloma patients also frequently develop bone lesions.
Bone metastases can cause a wide range of symptoms and
complications, such as pain, hypercalcemia, pathologic
fractures, and spinal cord compression, which may all se-
verely affect the quality of life of the patient. Skeletal me-
tastases are commonly classified as either osteolytic—
when the destruction of normal bone is the predominant
feature—or osteoblastic—when the deposition of new
bone predominates, although this distinction is not abso-
lute. Many lesions are mixed or impossible to classify on
radiological images, and bone markers often reveal that
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In the two types of lesions, there is a dysregulation of the
normal bone remodeling process.
The bone is commonly affected both in localized and
advancedprostatecancer,intheformermainlyasaresultof
prolonged androgen deprivation therapy (ADT) for locally
advanced disease, which causes cancer treatment–induced
bone loss (CTIBL), and in the latter by metastatic bone de-
struction with or without CTIBL caused by prolonged
ADT. Bone is the most common site of metastasis in pros-
tate cancer, affecting 85%–90% of men with advanced dis-
ease [1, 2]. It is a cause of significant morbidity such as
pain, pathologic fractures, nerve compression, and hyper-
calcemia. Once the disease has spread to the bone, prostate
cancerisincurable.Osteoporoticfracturesinducedbybone
metastases and CITBL are also a real clinical problem.
Clearly,newapproachesandnoveltherapiesarerequiredto
alter the course of aggressive metastatic disease and ame-
liorate the effects of ADT on bone mineral density (BMD).
The main therapeutic alternatives directed at treating
bonemetastasesinprostatecancerhavebeenexternalbeam
radiotherapy, radioisotope treatment, and intravenous
bisphosphonates (i.v. BPs), often in conjunction with ADT
or chemotherapy. Up to now, none of these treatments is
curative, but they are aimed to reduce the risk of skeletal-
related events (SREs), which in turn can increase quality of
life and life expectancy. Regarding CITBL prevention, no
approved therapeutic alternatives are available, but it is ex-
pected that some of the treatments indicated for bone me-
tastaseswillalsohelpreduceboneloss.Strontium-89(89Sr)
is the prototypic example of a bone-targeted radioisotope,
which functions as a calcium analogue preferentially taken
up at areas of increased bone turnover. In a phase III trial,
radioisotope treatment was associated with decreased opi-
oid usage and increased quality of life, but no survival ben-
efitorappreciableantitumoractivitywasobserved[3].BPs
are synthetic analogues of pyrophosphate, a physiologic
constituent of the bone matrix. They have the capacity to
inhibit, directly and indirectly, osteoclast activity, resulting
in decreased bone resorption [4]. Zoledronic acid was the
first BP to demonstrate efficacy in a phase III trial in reduc-
ing SREs in men with prostate cancer and bone metastases
[5], leading to approval in this indication by the European
Medicines Agency (EMA) in 2001 and the U.S. Food and
Drug Administration (FDA) in 2002.
Preclinicalandclinicalstudieshaveprovidedincreasing
insightintothephysiopathologyofbonemetastasesandos-
teoporosis, providing new potential therapeutic strategies.
On the basis of recent advances in the understanding of the
bone microenvironment and cancer cell interactions, the
development of new targeted therapies, capable of disrupt-
ingtheseinteractions,isbeingtested.Onemoleculethathas
proven central to osteoclast formation, function, and sur-
vival is the receptor activator of nuclear factor kappa B li-
gand (RANK-L). Denosumab is a fully human monoclonal
antibodyagainstRANK-Lthatisbeinginvestigatedinava-
riety of tumors. In the last year, results from several phase
III trials with denosumab in different clinical settings have
been presented. Here, we review present knowledge of the
role of RANK-L in bone physiopathology and the latest
clinical data on denosumab in prostate cancer and other tu-
mors.
THE ROLE OF RANK AND RANK-L IN THE
CONTROL OF NORMAL BONE REMODELING
Preclinical studies have discovered a complex system of
multiple interacting proteins and pathways that contribute
to the development of bone metastases. The activity of os-
teoclasts and osteoblasts is intricately coordinated to con-
tinually remodel the adult skeleton. There is a well-
balancedremodelingsequenceinnormalbone:boneisfirst
resorbed by osteoclasts and then regenerated by osteoblasts
to mature bone.
Osteoclasts arise from the monocyte-macrophage lin-
eage and, when they are activated, reabsorb bone and even-
tually undergo apoptosis. Locally produced cytokines and
systemic hormones regulate this physiological process.
Bone resorption is dependent on a cytokine known as
RANK-L, a TNF (tumor necrosis factor) family member
that is expressed on the surface of osteoblasts and is re-
leased by activated T-cells. Most osteotropic factors, such
as 1,25-dihydroxivitamin D3 or parathyroid hormone, in-
crease the expression of RANK-L, making it a key stimu-
lator of bone resorption. When RANK, expressed by both
osteoclasts and their precursors, binds to RANK-L, it stim-
ulates osteoclast formation [6], activation [7], adherence
[8], and survival [9], ultimately leading to increased bone
resorption. The catabolic effects of RANK-L are counter-
acted by osteoprotegerin (OPG), a TNF receptor family
member that binds RANK-L and thereby prevents activa-
tion of its single cognate receptor, RANK [10]. Osteoclast
activity is likely to depend, at least in part, on the relative
balance of RANK-L and OPG. Studies in numerous animal
modelsofbonediseaseshowthatRANK-Linhibitionleads
to marked suppression of bone resorption and increases in
cortical and cancellous bone volume, density, and strength
[11–13].
ThereareatleastthreeformsofRANK-L,twoofwhich
possess a transmembrane domain that positions the biolog-
ically active carboxy-terminus in the extracellular domain.
One of these forms, RANK-L2, is a shorter alternative
splicing variant of RANK-L1 [14]. Both variants can re-
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soluble forms that possess osteoclast-stimulating activities
within their TNF-homology domains [15, 16]. Numerous
cell types including cells of the osteoblast lineage [17] and
activated T cells [18] produce RANK-L. T cells express
bothsolubleandmembrane-boundformsofRANK-L[19],
and both forms are implicated in focal bone erosions as-
sociated with inflammatory arthritis. Cells of the osteo-
blast lineage can express RANK-L on their surface in a
manner that facilitates osteoclastogenesis in vitro via
cell-to-cell contact with osteoclast precursors [20]. In
mostsituations,RANK-Lprobablyreliesonmacrophage
colony-stimulated factor as a cofactor for osteoclast dif-
ferentiation [21].
The expression of RANK-L is controlled by numer-
ous cytokines and hormones, commonly known as regu-
lators of the immune system and calcium homeostasis
(Fig 1). Among the proresorptive factors are 1,25(OH)2
vitamin D3, parathyroid hormone (PTH) and parathyroid
hormone-related protein (PTHrP), prostaglandin E2, in-
terleukin-1 and -6, TNF, prolactin, and corticosteroids
(Fig. 2). However, estrogens, calcitonin, transforming
growth factor-, platelet-derived growth factor, and cal-
cium induce OPG expression, leading to neutralization
of RANK-L and thereby inhibition of osteoclastogenesis
and resorption [22].
RANK is the receptor that mediates all activities of
RANK-L. The binding and activation of RANK involves
direct interactions between the extracellular receptor bind-
ing domain of RANK-L and the extracellular cysteine-rich
domainsofRANK.Thisinteractioncausesoligomerization
Figure1. TheroleofRANK-Linboneformationandresorp-
tion. Adapted from Roodman, GD. Mechanisms of bone me-
tastasis. N Engl J Med 2004;350:1655–1664 with permission.
Copyright ©2004 Massachusetts Medical Society. All rights
reserved.
Abbreviations: BMP, bone morphogenic protein; CSF,
colony-stimulated factor; FGF, fibroblast growth factor; IGF,
insulin-like growth factor; IL, interleukin; PDGF, platelet-
derived growth factor; PTHrP, parathyroid hormone-related
protein; RANK, receptor activator of nuclear factor-kappa B;
RANKL, receptor activator of nuclear factor-kappa B ligand;
TGF, transforming growth factor; TNF-, tumor necrosis
factor-.
Figure 2. Factors implicated in bone resorption (A) and for-
mation (B).
Abbreviations: BMP, bone morphogenic protein; CSF,
colony-stimulated factor; FGF, fibroblast growth factor; IGF,
insulin-likegrowthfactor;PDGF,platelet-derivedgrowthfac-
tor; TGF, transforming growth factor; RANKL, receptor acti-
vator of nuclear factor-kappa B ligand.
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transduction pathways, especially protein kinase pathways
and transcription factors such as nuclear factor-kappa B
(NF-B). Activated NF-B upregulates the expression of
c-fos to induce the transcription of osteoclastogenic genes
[23].
THE ROLE OF RANK AND RANK-L IN THE
DEVELOPMENT OF BONE METASTASES
Recentevidenceindicatesthatosteoblasticmetastasesform
ontrabecularboneatsitesofpreviousosteoclastresorption.
In fact, such resorption is necessary for subsequent osteo-
blasticboneformation[24,25].Thesefindingssuggestthat
prostate cancer cells induce bone production through an
overall increase of bone remodeling [26]. In fact, animal
models of prostate cancer metastasis have shown that
skeletal lesions frequently exhibit increased osteoclast ac-
tivation and osteolysis, although bone metastases radiolog-
ically have an osteoblastic appearance [27]. When
neoplastic cells from prostate cancer metastasize to bone,
they initially induce osteoclastogenesis and bone resorp-
tion.RANK,RANK-L,anditssolubledecoyreceptorOPG
play an essential role in the regulation of this process [28].
It has been shown that metastatic prostate cancer cells in
bone (and not at other sites) express both RANK-L and its
“antagonist” OPG. OPG, however, seems to have a primar-
ilynuclearlocalizationinthesecells,whereasnormallyitis
expressed in the cytoplasm. This could affect the bioavail-
abilityofthisprotein[29].Similarfindingshavebeenmade
in in vitro experiments with multiple myeloma cells [30].
Breast cancer cells have been shown not only to express
RANK [31] but also to upregulate RANK-L expression by
osteoblasts and bone marrow stromal cells [32]. Prostate
cancer cells can also upregulate RANK-L expression in os-
teoblasts [33].
PRECLINICAL AND EARLY CLINICAL DATA
ON DENOSUMAB
Denosumab is a fully human monoclonal antibody with a
high affinity and specificity for RANK-L and can thus bind
and thereby neutralize the activity of RANK-L in a similar
fashion as OPG. Denosumab, as other fully human thera-
peuticantibodies,hasbeenproducedintransgenicmice,by
deleting their murine immunoglobulin genes and replacing
them with human orthologs [34]. The activity of deno-
sumab is primate-specific, and it cannot be tested in rat
modelsofbonemetastasis.However,becauseOPGandde-
nosumabhavesimilarmechanismsofaction,OPGhasbeen
used as a surrogate for the study of RANK-L inhibition in
animal models. These experiments have shown that OPG
markedly reduces osteoclast numbers in bone lesions that
resulted from direct intratibial injection of human prostate
cancer cells into immunodeficient mice [35]. Experiments
inratshaveshownthatasingleinjectionofOPGresultedin
a rapid (within 12 hours) and deep (up to 95%) reduction in
the percentage of bone surfaces occupied by osteoclasts,
which then gradually returned to normal from days 10–30
after injection as the drug is cleared from the circulation.
Osteoblast surface and biochemical markers of osteoblast
activity were more modestly suppressed. These changes
wereassociatedwithaprogressiveincreaseinbonemineral
density at day 30 compared with controls [36].
The marked suppression of bone turnover associated
with RANK-L inhibition raises the question of the possible
consequences of long-term therapy to bone strength and
bone quality. Non-human primates represent the most ap-
propriate preclinical species for evaluating the skeletal re-
sponse to therapeutic intervention. In young gonad-intact
monkeys, three months of OPG treatment led to significant
reductions in biochemical markers of bone turnover [37].
OPG treatment was associated with decreases in serum-
ionized calcium and phosphorus levels, an expected conse-
quence of suppressed bone resorption, and a secondary
increase in serum PTH levels. In this study, the treatment
increased BMD. There were no treatment-related clinical
observationsandnotreatment-relatedhistopathologicfind-
ings in animals treated for 1 or 3 months with OPG. Simi-
larly, 12 months of denosumab treatment in cynomolgus
monkeys was associated with significant increases in bone
strength [38].
Moving into clinical trials in humans, two phase I trials
have been conducted with denosumab in cancer patients.
Bodyetal.[39]developedaphaseIstudylookingatsafety,
pharmacokinetics, and pharmacodynamics of a single sub-
cutaneous injection in patients with breast cancer or multi-
ple myeloma. Patients received a single dose of either
denosumab (0.1, 0.3, 1.0, or 3.0 mg/kg) or pamidronate (90
mg iv). The most common adverse events were fatigue and
asthenia, and no serious drug-related adverse events were
reported.Pharmacokineticsstudiesshowedarapidandpro-
longed absorption, starting 1 hour postdose and reaching
maximum serum levels as late as 21 days later. Effects on
boneresorptionwereassessedbychangesinurinaryandse-
rum N-telopeptide (NTX) levels. In patients treated with
denosumab, levels decreased within 1 day and this effect
lasted through day 84 in the higher dose levels, whereas the
effect of pamidronate reached a maximum at 3 days and
started to rise again on day 28. The other phase I trial was
carried out in 18 Japanese patients who received a single
subcutaneous injection of 60 or 180 mg or three doses of
180 mg every 4 weeks. No major safety concerns or dose-
limiting toxicities were noted in any cohort. Denosumab
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urine NTX (uNTX). The median change of UNTX cor-
rected for urine creatinine (uNTx/Cr) from baseline ranged
from 61.9% to 90.8% [40].
The optimal dose regimen has been studied in a phase II
trialevaluatingfivedoseregimensofdenosumabin255pa-
tients with bone metastases not previously treated with i.v.
BPs.Patientswererandomizedtoreceiveeitherdenosumab
or i.v. BP. Denosumab was administered subcutaneously
eitherevery4weeks(30,120,or180mg)orevery12weeks
(60 or 180 mg), and the i.v. BP was administered every 4
weeks.Theprimaryendpointwasmedianpercentchangein
uNTX/Cr from baseline to week 13. Overall, 74% of deno-
sumab-treated patients achieved a reduction in uNTx of
65%,comparedwith63%ofi.v.BPtreatedpatientswith-
out any unexpected serious adverse events related to study
treatment. The dose regimen showing the greatest suppres-
sion of bone resorption seems to be 120 mg every 4 weeks,
according to this study. The authors conclude that these
data suggest that denosumab may be similar to i.v. BP in
both efficacy and safety [41].
Recently published results from a randomized phase II
trial of denosumab versus continued i.v. BP provide in-
sights on the effect of denosumab in patients previously
treated with an i.v. BP. The trial included 111 patients with
bone metastases from prostate cancer, breast cancer, multi-
ple myeloma, or other solid neoplasms currently receiving
i.v. BP. Eligible patients for this study had at least 1 bone
metastasis, and uNTx levels  50 nmol/L bone collagen
equivalents/mMcreatininedespiteongoingi.v.BPtherapy.
Theprimaryendpointofthestudywasthepercentageofpa-
tients with an uNTx  50 at week 13 and was reached by
71% of the patients on the denosumab arm and 29% in the
i.v. BP arm (p  .001). This difference diminished slightly
over time: at 25 weeks of follow-up, 64% versus 37% (p 
.01), respectively, of patients maintained an uNTx 50.
TherewasalsoanonsignificanttrendtowardfewerSREsin
the denosumab group versus the i.v. BP group (8% versus
17%, respectively). The study shows that denosumab nor-
malized uNTx levels more frequently than continued i.v.
BP therapy, whereas the rate of adverse events was similar
between the two groups [42].
Several other phase II trials are being conducted, and
there are at present 23 phase III trials registered with deno-
sumab in http://www.clinicaltrials.gov, 10 of which are in
theoncologicalsetting.Therestofthisreviewwillfocuson
the most important trials with this compound in cancer pa-
tients, including recently presented results.
CLINICAL STUDIES OF DENOSUMAB IN
PROSTATE CANCER
ThreephaseIIItrialsarecurrentlyongoingtodeterminethe
efficacy of denosumab in men with prostate cancer (Table 1).
There is no approved therapy for the prevention of bone
Table 1. Ongoing trials of denosumab for breast cancer, multiple myeloma, and prostate cancer
(http://www.clinicaltrials.gov)
Study/design N Study population Arms Primary endpoint
Prostate cancer
NCT00321620/phase III 1901 Hormone refractory
nonmetastatic prostate cancer
Denosumab vs
zoledronic acid
Time to first on-study SRE
(noninferiority test)
NCT00089674/phase III 1468 Androgen deprivation therapy for
nonmetastasic prostate cancer
Denosumab vs placebo % change from baseline in
lumbar spine BMD
NCT00286091/phase III 1435 Hormone refractory prostate
cancer without bone metastases
Denosumab vs placebo Time to first ocurrance of
bone metastasis or death
Breast cancer
NCT00321464/phase III 2046 Advanced breast cancer Denosumab vs
zoledronic acid
Time to first on-study SRE
NCT00556374/phase III 2800 Nonmetastatic breast cancer
receiving AI
Denosumab vs placebo Time to first clinical
fracture
Other solid tumors
and multiple myeloma
NCT00259740/phase II 96 Relapsed or plateau-phase MM Denosumab CR or PR to treatment
(serum M protein)
NCT00330759/phase III 1776 Advanced cancer (excluding
breast and prostate) and MM
Denosumab vs
zoledronic acid
Time to first on-study SRE
(noninferiority test)
Abbreviations: AI, aromatase inhibitors; BMD, bone mass density; CR, complete response; MM, multiple myeloma; PR,
partial response; SRE, skeletal-related event.
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though by extrapolation of data from studies in osteoporo-
sis, many physicians use both oral and i.v. BPs in this
setting. Several phase III clinical trials with denosumab ad-
dress its use in the setting of postmenopausal osteoporosis,
confirming its capacity to increase BMD, decrease bone
turnover, and reduce fracture in this population [43–45].
Recent results have also confirmed its efficacy in reducing
CTIBL in both prostate and breast cancer, as follows.
NCT00089674, also known as the HALT-prostate can-
cer trial, was a randomized double-blind, placebo-con-
trolled phase III trial that accrued 1468 men with
nonmetastatic prostate cancer receiving ADT. The purpose
wastoevaluatedenosumabinthepreventionofbonelossin
this group of patients. The subjects were randomized to ei-
ther60mgofdenosumabbysubcutaneousinjectionevery6
months or placebo, together with calcium and vitamin D
supplements. The primary endpoint was percent change of
BMD in the lumbar spine after 24 months of treatment, and
fracture rate was a secondary endpoint. The results indi-
cated a significant difference between the two treatment
arms,witha5.6%increaseinBMDinthedenosumabgroup
and a 1.0% decrease in the placebo group (p  .001). There
was also a significant difference in vertebral fracture rate at
36 months in favor of denosumab: 1.5% versus 3.9% (p 
.006).Ratesofadverseeventsweresimilarbetweenthetwo
groups,andnocasesofosteonecrosisofthejaw(ONJ)were
reported [46].
Trial NCT00321620 was a phase III randomized dou-
ble-blind, double-dummy trial that compared the efficacy
and safety of denosumab versus zoledronic acid in 1901
menwithprostatecancer,bonemetastasis,anddiseasepro-
gression despite ADT (without prior i.v. BP use). The pri-
mary endpoint was time to first on-study SRE, defined as
pathological fracture, radiation to bone, surgery to bone, or
spinal cord compression. Patients were randomized to re-
ceive either subcutaneous denosumab 120 mg and i.v. pla-
cebo (n  950), or subcutaneous placebo and i.v.
zoledronic acid 4 mg (n  951). Denosumab significantly
delayed the time to first on-study SRE (median of 20.7
months versus 17.1 months with zoledronic acid; p  .008)
(Table 2), as well as the time to first and subsequent on-
study SRE (p  .004). A greater suppression of the bone
turnover markers uNTx and bone-specific alkaline phos-
phatasewasalsoobservedindenosumabpatientscompared
with zoledronic acid (p  .0001 for both). Adverse event
rates were similar, irrespective of potential relationship to
study drugs. Hypocalcemia was reported in 13% and 6% of
denosumab and zoledronic acid patients. Overall survival
(p  .65) and time to cancer progression (p  .30) were
similar between the two arms. These results demonstrated
thesuperiorityofdenosumaboverzoledronicacidindelay-
ing or preventing SREs in patients with bone metastases
from hormone-refractory prostate cancer [47].
NCT00286091 is a trial with a slightly different aim: to
study a possible metastasis-preventive effect of deno-
sumab. It is a randomized double-blind, placebo-controlled
phase III trial of 1435 patients with hormone refractory
prostate cancer with no bone metastases at baseline but a
rising prostate-specific antigen (PSA) despite ADT. Only
patients at high risk for development of bone metastasis
based on PSA  8 ngs/dl and/or PSA doubling time  10
months are included. The primary endpoint is bone metas-
tasis-free survival. Enrollment has concluded, and first re-
sults are awaited soon (http://clinicaltrials.gov).
CLINICAL STUDIES OF DENOSUMAB IN
BREAST CANCER
Breast cancer can induce several osteotropic factors that in
turn induce RANK-L production by stromal cells in bone
marrow. In experimental models, breast cancer cells in-
crease stromal cell expression of RANK-L [48], probably
through the effects of PTHrP [49]. In stromal tissue sur-
roundingabreastcancer,thelevelsofstromalRANK-Lare
increased, although with no effect on circulating levels. As
a response to high RANK-L levels, OPG also rises and
binds excess RANK-L [50].
Intheclinicalsetting,theeffectsofdenosumabinbreast
cancer patients have been extensively studied during the
last several years. One patient population of special interest
is women with hormone receptor-positive breast cancer re-
ceiving adjuvant aromatase inhibitors, due to the increased
risk of developing osteopenia and osteoporosis. Results
have been published from a randomized phase III study
(NCT00089661,alsoknownastheHALT-BCtrial)includ-
ing252patientsinthisclinicalsetting.Theywererandomly
assigned to receive either 60 mg of subcutaneous deno-
Table 2. Time to first on-study skeletal-related event in
the three pivotal phase III trials 47, 52, 59
Hazard ratio
Study/design
Point
estimate 95% CI
p-
value
Breast cancer (N  2046) 0.82 (0.71, 0.95) .01
Prostate cancer (N  1901) 0.82 (0.71, 0.95) .008
Other solid tumors or 0.84 (0.71, 0.98) .06
multiple myeloma
(N  1776)
Hazard ratio 1 favors denosumab.
Abbreviations: CI, confidence interval; SRE, skeletal-
related event.
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tients), and all received supplementary vitamin D and
calcium. The primary outcome measure was change in
BMD. At 12 and 24 months, lumbar spine BMD had in-
creased by 5.5% and 7.6%, respectively, in the denosumab
arm versus placebo (p  .0001), with decreased bone turn-
overmarkersinthedenosumabgroup.Nodifferencesinad-
verse events were found between the two groups [51].
Another phase III study (NCT00556374, the ABCSG-18
trial) in this population is currently recruiting patients for
randomization to either denosumab treatment or placebo in
conjunction with the aromatase inhibitors treatment. The
primary endpoint in this trial, however, is time to first clin-
ical fracture. Accrual is ongoing with the goal of including
2800 patients.
The trial NCT00321464 is a randomized phase III trial
comparingdenosumabwithzoledronicacidinpatientswith
metastatic breast cancer. The primary endpoint is time to
firston-studySRE.Thefirstresultswererecentlypresented
confirmingthesuperiorityofdenosumabindelayingorpre-
venting the onset of the first on-study SRE (hazard ratio
[HR] 0.82; 95% confidence interval [CI]: 0.71–0.95; p 
.01), as well as subsequent SREs (HR 0.77; 95% CI: 0.66–
0.89; p  .001) (Table 2). There were no significant differ-
ences in the frequency of adverse events, including some
cases of ONJ in both treatment arms [52].
CLINICAL STUDIES OF DENOSUMAB IN OTHER
SOLID TUMORS AND MULTIPLE MYELOMA
Inmultiplemyeloma,80%ofpatientsdeveloposteopenia
or osteolytic lesions due to increased bone resorption
caused by stimulation of osteoclast formation and activity
[53–55]. This increased osteoclast activity is accompanied
by decreased or absent osteoblast function. Several studies
have identified potential novel targets for treating bone dis-
ease in multiple myeloma including the Wingless-type and
the RANK-L pathways [56]. Focusing on the latter, Giu-
liani et al. [57] and other authors have reported that there is
animbalancebetweenOPGandRANK-Llevelsinthebone
marrow environment of patients with multiple myeloma,
although the cell source for RANK-L production in the mi-
croenvironment remains controversial. Vij et al. [58] re-
cently reported the results of a phase II trial in patients with
plateau-phase or progressive multiple myeloma, demon-
strating that denosumab significantly inhibited the
RANK-L pathway as demonstrated by decreased levels of
boneturnovermarkers,althoughtheprincipalhypothesisof
the study—a possible cytotoxic effect of RANK-L inhibi-
tion—could not be confirmed.
The results from a randomized, double-blind phase
III trial (NCT00330759), comparing denosumab with
zoledronic acid in the treatment of bone metastases in 1776
patients with advanced cancer or multiple myeloma and no
previous i.v. BP therapy, were also recently presented. The
patientswererandomizedtoreceiveeither120mgofdeno-
sumab or 4 mg of zoledronic acid every 4 weeks, and all
were recommended to take vitamin D and calcium supple-
ments. Denosumab delayed the time to first on-study SRE
(pathologic fracture, radiation therapy or surgery to bone,
or spinal cord compression) and was noninferior to
zoledronic acid (HR 0.84; 95% CI: 0.71–0.98; p  .0007).
Themediantimetofirston-studySREwas20.6monthsfor
denosumab and 16.3 months for zoledronic acid. Although
numerically greater, the delay in time to first on-study SRE
with denosumab was not superior to zoledronic acid based
upon the statistical testing strategy (adjusted p  .06) (Ta-
ble 2). Time to first and subsequent SRE was numerically
greater for denosumab (HR 0.90; 95% CI: 0.77–1.04; p 
.14). The overall incidence of adverse events was similar
betweenthetwogroups,includingthereportedrateofONJ:
1.1%and1.3%inthedenosumabandzoledronicacidarms,
respectively [59]. Although this study showed a trend to-
ward superiority of denosumab versus zoledronic acid in
delaying the time to first on-study SRE in patients with ad-
vancedsolidtumorsandmultiplemyeloma,furthertrialsin
myeloma patients are needed to support the use of deno-
sumab in this population. A subset analysis of the same
study presented at the American Society of Clinical Oncol-
ogy (ASCO) 2010 meeting compared the treatment effects
inonlypatientswithsolidtumorsandbonemetastases(n
1597) [60]. Denosumab significantly delayed the time to
the first on-study SRE compared with zoledronic acid (HR
0.81; 95% CI: 0.68–0.96; p  .02) and also delayed the
time to first and subsequent SREs (HR 0.85; 95% CI: 0.72–
1.00; p  .05). These results support that denosumab is
more effective than zoledronic acid in patients with solid
tumors and bone metastases.
SAFETY PROFILE
Generally speaking, denosumab is well tolerated. Perhaps
the most comprehensive safety analysis that is publicly
available is the FDA’s analysis of the currently available
evidence in relation to its evaluation of this drug for treat-
ment of postmenopausal women who have a high risk for
osteoporotic fractures (60 mg dose administered every 6
months) [61]. Looking at placebo-controlled phase III tri-
als, there are few adverse events that differ clearly in inci-
dence between denosumab and placebo groups. Some of
the most frequently reported adverse events are arthralgia,
back pain, pain in extremity, musculoskeletal pain, periph-
eral edemas, cough, and dizziness. The most commonly al-
tered laboratory value is serum calcium levels, where
142 Denosumab in Cancer Patientsdenosumab can cause hypocalcemia that is, however, usu-
ally transient and rarely symptomatic. Nadir for serum cal-
cium after a dose of denosumab is reached around day 10.
Therearecurrentlynoindicationsthattreatmentwithdeno-
sumab may lead to impaired renal function.
Intermsofpossibleseriousdrug-relatedadverseevents,
there has been a concern that denosumab may increase the
risk of serious infections or immune reactions, due to the
fact that RANK-L is expressed on T and B cells as well.
Although according to the FDA report patients treated with
60 mg of denosumab every 6 months had a slightly in-
creased incidence of serious infections (4.1% for deno-
sumab versus 3.3% for placebo), the incidence of overall
infections and opportunistic infections did not differ be-
tween groups.
AnotherconcernisthepossibilityofONJ.Apreplanned
integratedanalysisofthethreetrialscomparingdenosumab
with zoledronic acid for preventing skeletal-related events
in cancer patients with bone metastases [62] found that,
among 5673 patients who received at least one treatment
dose,ONJoccurredin1.8%(n52)ofdenosumab-treated
patients and 1.3% (n  37) of zoledronic acid–treated pa-
tients (p  .13). The majority of these patients experienced
atleastoneknownriskfactor(81%inbotharmshadunder-
gone tooth extraction, had poor oral hygiene, or used a den-
tal appliance; 67% and 73%, respectively, had received
chemotherapy; and 10% and 22% had received prior anti-
angiogenic therapy). ONJ resolution during the study oc-
curred in 35% of denosumab- and 27% of zoledronic acid–
treated patients. These data suggest that ONJ risk with
denosumab is the same as with zoledronic acid and that
some preventive actions should be undertaken prior to and
during treatment.
CONCLUSIONS AND FUTURE DIRECTIONS
Metastaticdiseasetothebonehad,duringthewholehistory
of cancer treatment, been a cruelly crippling complication
of the tumor, leaving many patients bedridden or wheel-
chair-bound. With the advent of the iv BPs this changed
radically, by progressively reducing the risk of SREs with
increasingpotencyofthedrugs[63].Asclinicalexperience
with these drugs increased, however, awareness also in-
creased regarding their safety profile and the potential risk
of ONJ. This occasionally disfiguring and mutilating com-
plication, the real incidence of which is not quite ascer-
tained,changedtherisk-benefitratiofortheuseofi.v.BPin
metastatic disease. Great effort has been put into discover-
ing the pathophysiology of ONJ and possible ways to pre-
ventit,andprogresshasbeenmade,whichonceagainshifts
thescaletowardthebenefitside.Theinclusionofnewphar-
macological alternatives in the treatment of bone metasta-
seswillmostprobablybethebestwaytofurthertilttherisk-
benefit scale in the right direction for these patients.
Denosumab represents a new therapeutic approach by
targeting the RANK-L pathway essential for osteoclast dif-
ferentiation,activation,andfunction,andwhoseexpression
seems to be induced by cancer cells. In oncology it is being
developed in two specific areas: prevention and treatment
of CTIBL, and treatment of bone metastases. Recent clini-
cal data demonstrate that denosumab is well tolerated and
effective in increasing BMD and reducing bone turnover
and fracture rates versus placebo. Phase III data also con-
firm its efficacy in preventing or delaying SREs in patients
withmetastaticdiseaseofthebone.Intermsofefficacy,itis
as good as, and perhaps better than, zoledronic acid. The
subcutaneous route of administration adds convenience to
patients as well. The overall safety profile seems to be
clearly manageable, although treatment with denosumab is
still associated with a low risk of ONJ, similar to that ob-
served with i.v. BPs. Prevention of this entity in deno-
sumab-treated patients is recommended. Prior to initiating
therapy, a routine dental clinical examination should be
performed. All patients should be instructed to avoid elec-
tive invasive dental procedures, and routine oral assess-
ments during treatment should be scheduled.
In conclusion, denosumab has added benefits that may
help in the search for the optimal treatment of metastatic
disease to the bone. Most of the phase II and III trials with
denosumab in oncology have completed accrual but have
yet to present their results. Much new information will be
gained about RANK-L inhibition in general and deno-
sumab in particular, to further improve quality of life in
cancer patients.
ACKNOWLEDGMENTS
Amgen S.A. has provided funds to support the editing of
thismanuscript.Theconclusions,interpretations,andopin-
ions expressed herein are those of the authors.
AUTHOR CONTRIBUTIONS
Conception/Design: Daniel Castellano, Juan Manuel Sepulveda
Provision of study material or patients: Daniel Castellano, Anna Sundlo ¨v
Collection and/or assembly of data: Daniel Castellano, Anna Sundlo ¨v
Dataanalysisandinterpretation:DanielCastellano,JuanManuelSepulveda,
Ignacio Garcı ´a-Escobar, Alfredo Rodriguez-Antolı ´n, Anna Sundlo ¨v,
Herna ´n Cortes-Funes
Manuscript writing: Daniel Castellano, Juan Manuel Sepulveda, Anna
Sundlo ¨v
Final approval of manuscript: Daniel Castellano, Juan Manuel Sepulveda,
IgnacioGarcı ´a-Escobar,AlfredoRodriguez-Antolı ´n,AnnaSundlo ¨v,Herna ´n
Cortes-Funes
The authors take full responsibility for the content of the paper but thank Dr.
Sundlo ¨v, who received funds as a medical writer to provide editorial support.
143 Castellano, Sepulveda, García-Escobar et al.
www.TheOncologist.comREFERENCES
1 Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mi-
toxantrone plus prednisone for advanced prostate cancer. New Engl J Med
2004;351:1502–1512.
2 Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine
compared with mitoxantrone and prednisone for advanced refractory pros-
tate cancer. New Engl J Med 2004;351:1513–1520.
3 Porter AT, McEwan AJ, Powe JE et al. Results of a randomized phase-iii
trial to evaluate the efficacy of strontium-89 adjuvant to local field external
beam irradiation in the management of endocrine resistant metastatic pros-
tate cancer. Int J Radiat Oncol Biol Phys 1993;25:805–813.
4 MichaelsonMD,SmithMR.Bisphosphonatesfortreatmentandprevention
of bone metastases. J Clin Oncol 2005;23:8219–8224.
5 Saad F, Gleason DM, Murray R et al. A randomized, placebo-controlled
trialofzoledronicacidinpatientswithhormone-refractorymetastaticpros-
tate carcinoma. J Natl Cancer Inst 2002;94:1458–1468.
6 MatsuzakiK,UdagawaN,TakahashiNetal.Osteoclastdifferentiationfac-
tor(ODF)inducesosteoclast-likecellformationinhumanperipheralblood
mononuclearcellcultures.BiochemBiophysResCommun1998;246:199–
204.
7 Burgess TL, Qian Y, Kaufman S et al. The ligand for osteoprotegerin
(OPGL) directly activates mature osteoclasts. J Cell Biol 1999;145:527–
538.
8 O’Brien EA, Williams JH, Marshall MJ. Osteoprotegerin ligand regulates
osteoclast adherence to the bone surface in mouse calvaria. Biochem Bio-
phys Res Commun 2000;274:281–290.
9 Lacey DL, Tan HL, Lu J et al. Osteoprotegerin ligand modulates murine
osteoclast survival in vitro and in vivo. Am J Pathol 2000;157:435–448.
10 Schneeweis LA, Willard D, Milla ME. Functional dissection of osteopro-
tegerinanditsinteractionwithreceptoractivatorofnf-kappabligand.JBiol
Chem 2005;280:41155–41164.
11 Morony S, Capparelli C, Sarosi I et al. Osteoprotegerin inhibits osteolysis
and decreases skeletal tumor burden in syngeneic and nude mouse models
of experimental bone metastasis. Cancer Res 2001;61:4432–4436.
12 Tometsko M, Roudier M, Canon J et al. RANK-L inhibition causes a
greater suppression of tumor-induced osteoclastogenesis than zoledronate
treatmentinvivoandRANK-Lrescuesosteoclastsfromzoledronatekilling
in vitro. Am Soc Bone Miner Res 2006;21(suppl 1):Abstract M076.
13 Morony S, Warmington K, Tan H et al. OPG inhibits the progression of
bone destruction and skeletal tumor burden in mice with established osteo-
lytic MDA-231 breast cancer metastases. J Bone Miner Res 2002;17:S147.
14 Anderson DM, Maraskovsky E, Billingsley WL et al. A homologue of the
TNF receptor and its ligand enhance t-cell growth and dendritic-cell func-
tion. Nature 1997;390:175–179.
15 IkedaT,KasaiM,UtsuyamaMetal.Determinationofthreeisoformsofthe
receptor activator of nuclear factor-B ligand and their differential expres-
sion in bone and thymus. Endocrinology 2001;142:1419.
16 Hikita A, Yana I, Wakeyama H et al. Negative regulation of osteoclasto-
genesis by ectodomain shedding of receptor activator of nf-kappab ligand.
J Biol Chem 2006;281:36846.
17 Nakamichi Y, Udagawa N, Yasuda H et al. M-CSF independent mecha-
nisms for osteoclastogenesis. J Bone Miner Res 2007;22:S380.
18 Fuller K, Wong B, Fox S et al. TRANCE is necessary and sufficient for
osteoblast-mediatedactivationofboneresorptioninosteoclasts.JExpMed
1998;188:997–1001.
19 Kong YY, Feige U, Sarosi I et al. Activated T cells regulate bone loss and
joint destruction in adjuvant arthritis through osteoprotegerin ligand. Na-
ture 1999;402:304–309.
20 Udagawa N, Takahashi N, Yasuda H et al. Osteoprotegerin produced by
osteoblasts is an important regulator in osteoclast development and func-
tion. Endocrinology 2000;141:3478–3484.
21 Quinn JM, Elliott J, Gillespie MT et al. A combination of osteoclast differ-
entiation factor and macrophage-colony stimulating factor is sufficient for
both human and mouse osteoclast formation in vitro. Endocrinology 1998;
139:4424–4427.
22 Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activa-
tion. Nature 2003;423:337–342.
23 Boyce BF, Xing L. Biology of RANK, RANK-L, and osteoprotegerin. Ar-
thritis Res Ther 2007;1(suppl 9):S1.
24 ZhangJ,DaiJ,QiYetal.Osteoprotegerininhibitsprostatecancer-induced
osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin
Invest 2001;107:1235–1244.
25 Carlin BI, Andriole GL. The natural history, skeletal complications, and
management of bone metastases in patients with prostate carcinoma. Can-
cer 2000;88(suppl 12):2989–2994.
26 Boyce BF, Hughes DE, Wright KR et al. Recent advances in bone biology
provide insight into the pathogenesis of bone diseases. Lab Invest 1999;79:
83–94.
27 Yonou H, Kanomata N, Goya M et al. Osteoprotegerin/osteoclastogenesis
inhibitory factor decreases human prostate cancer burden in human adult
bone implanted into nonobese diabetic/severe combined immunodeficient
mice. Cancer Res 2003;63:2096–2102.
28 Wada T, Nakashima T, Hiroshi N et al. RANK-L–RANK signaling in os-
teoclastogenesis and bone disease. Trends Mol Med 2006;12:17–25.
29 Brown JM, Corey E, Lee ZD et al. Osteoprotegerin and rank ligand expres-
sion in prostate cancer. Urology 2001;57:611–616.
30 Farrugia AN, Atkins GJ, To LB et al. Receptor activator of nuclear factor-
kappabligandexpressionbyhumanmyelomacellsmediatesosteoclastfor-
mation in vitro and correlates with bone destruction in vivo. Cancer Res
2003;63:5438–5445.
31 Jones DH, Nakashima T, Sanchez O et al. Regulation of cancer cell migra-
tion and bone metastasis by RANKL. Nature 2006;440:692–696.
32 Thomas RJ, Guise TA, Yin JJ et al. Breast cancer cells interact with osteo-
blasts to support osteoclast formation. Endocrinology 1999;140:4451–
4458.
33 Fizazi K, Yang J, Peleg S et al. Prostate cancer cells-osteoblast interaction
shiftsexpressionofgrowth/survival-relatedgenesinprostatecancerandre-
duces expression of osteoprotegerin in osteoblasts. Clin Cancer Res 2003;
9:2587–2597.
34 Weiner LM. Fully human therapeutic monoclonal antibodies. J Immu-
nother 2006;29:1–9.
35 ZhangJ,DaiJ,QiYetal.Osteoprotegerininhibitsprostatecancer-induced
osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin
Invest 2001;107:1235–1244.
36 Capparelli C, Morony S, Warmington K et al. Sustained antiresorptive ef-
fects after a single treatment with human recombinant osteoprotegerin
(OPG): A pharmacodynamic and pharmacokinetic analysis in rats. J Bone
Miner Res 2003;18:852–858.
37 Smith BB, Cosenza ME, Mancini A et al. A toxicity profile of osteoprote-
gerin in the cynomolgus monkey. Int J Toxicol 2003;22:403–412.
38 Atkinson J, Cranmer P, Saunders T et al. AMG 162, a fully human
RANK-L antibody, increases bone mass and bone strength in cynomolgus
monkeys. J Bone Miner Res 2005;20:S29.
144 Denosumab in Cancer Patients39 Body JJ, Facon T, Coleman RE et al. A study of the biological receptor
activator of nuclear factor-kappab ligand inhibitor, denosumab, in patients
withmultiplemyelomaorbonemetastasesfrombreastcancer.ClinCancer
Res 2006;12:1221–1228.
40 Yonemori K, Fujiwara Y, Minami H et al. Phase 1 trial of denosumab
safety,pharmacokinetics,andpharmacodynamicsinJapanesewomenwith
breast cancer-related bone metastases. Cancer Sci 2008;99:1237–1242.
41 LiptonA,StegerGG,FigueroaJetal.Randomizedactive-controlledphase
II study of denosumab efficacy and safety in patients with breast cancer-
related bone metastases. J Clin Oncol 2007;25:4431–4437.
42 Fizazi K, Lipton A, Mariette X et al. Randomized phase II trial of deno-
sumabinpatientswithbonemetastasesfromprostatecancer,breastcancer,
or other neoplasms after intravenous bisphosphonates. J Clin Oncol 2009;
27:1564–1571.
43 Bone HG, Bolognese MA, Yuen CK et al. Effects of denosumab on bone
mineral density and bone turnover in postmenopausal women. J Clin En-
docrinol Metab 2008;93:2149–2157.
44 Lewiecki EM, Miller PD, McClung MR et al. Two-year treatment with de-
nosumab (AMG 162) in a randomized phase 2 study of postmenopausal
women with low BMD. J Bone Miner Res 2007;22:1832–1841.
45 McClung MR, Lewiecki EM, Cohen SB et al. Denosumab in postmeno-
pausal women with low bone mineral density. New Engl J Med 2006;354:
821–831.
46 Smith MR, Egerdie B, Herna ´ndez Toriz N et al. Denosumab in men receiv-
ing androgen-deprivation therapy for prostate cancer. New Engl J Med
2009;361:745–755.
47 Fizazi K, Carducci MA, Smith MR et al. A randomized phase III trial of
denosumab versus zoledronic acid in patients with bone metastases from
castration-resistant prostate cancer. J Clin Oncol 2010;28:18s.
48 Kitazawa S, Kitazawa R. RANK ligand is a prerequisite for cancer-associ-
ated osteolytic lesions. J Pathol 2002;198:228–236.
49 Thomas RJ, Guise TA, Yin JJ et al. Breast cancer cells interact with osteo-
blasts to support osteoclast formation. Endocrinology 1999;140:4451–
4458.
50 Grimaud E, Soubigou L, Couillaud S et al. Receptor activator of nuclear
factor kappab ligand (RANK-L)/osteoprotegerin (OPG) ratio is increased
in severe osteolysis. Am J Pathol 2003;163:2021–2031.
51 EllisGK,BoneHG,ChlebowskiRetal.Randomizedtrialofdenosumabin
patients receiving adjuvant aromatase inhibitors for nonmetastatic breast
cancer. J Clin Oncol 2008;26:4875–4882.
52 StopeckA,BodyJJ,FujiwaraY.Denosumabversuszoledronicacidforthe
treatment of breast cancer patients with bone metastases: Results of a ran-
domized phase 3 study. Eur J Cancer Suppl 2009;7:2.
53 Melton LJ, Kyle RA, Achenbach SJ et al. Fracture risk with multiple my-
eloma: A population-based study. J Bone Miner Res 2005;20:487–493.
54 Barille ´-Nion S, Bataille R. New insights in myeloma-induced osteolysis.
Leukemia Lymphoma 2003;44:1463–1467.
55 Giuliani N, Colla S, Rizzoli V. New insight in the mechanism of osteoclast
activation and formation in multiple myeloma: focus on the receptor acti-
vator of nf-kappab ligand (RANK-L). Exp Hematol 2004;32:685–691.
56 OshimaT,AbeM,AsanoJetal.Myelomacellssuppressboneformationby
secreting a soluble wnt inhibitor, sfrp-2. Blood 2005;106:3160–3165.
57 Giuliani N, Bataille R, Mancini C et al. Myeloma cells induce imbalance in
the osteoprotegerin/osteoprotegerin ligand system in the human bone mar-
row environment. Blood 2001;98:3527–3533.
58 Vij R, Horvath N, Spencer A et al. An open-label, phase 2 trial of deno-
sumab in the treatment of relapsed or plateau-phase multiple myeloma.
Am J Hematol 2009;84:650–656.
59 Henry D, von Moos R, Vadhan-Raj S et al. A double-blind, randomized
study of denosumab versus zoledronic acid for the treatment of bone me-
tastases in patients with advanced cancer (excluding breast and prostate
cancer) or multiple myeloma. Eur J Cancer Suppl 2009;7:12.
60 Henry HD, von Moos R, Hungria V et al. Delaying skeletal-related events
in a randomized phase III study of denosumab versus zoledronic acid in
patients with advanced cancer. J Clin Oncol 2010;28:15s.
61 Background Document for Meeting of Advisory Committee for Reproduc-
tive Health Drugs. FDA report, August 13, 2009. Available at http://www.
fda.gov [database]. Accessed February 1, 2010.
62 Brown JE, Barrios CE, Diel IJ et al. Incidence and outcomes of osteone-
crosis of the jaw from an integrated analysis of three pivotal randomized
double-blind, double-dummy phase 3 trials comparing denosumab and
zoledronic acid for treatment of bone metastases in advanced cancer pa-
tients or myeloma. Bone 2011;48:S18–S19.
63 Lipton A. Bisphosphonates and breast carcinoma: present and future. Can-
cer 2000;88(suppl 12):3033–3037.
145 Castellano, Sepulveda, García-Escobar et al.
www.TheOncologist.com